CDK4/6 Inhibitors-Induced Macrocytosis Is Not Associated with Hemolysis and Does Not Impact Hemoglobin Homeostasis

• Published in: Cancers Vol. 17; no. 9; p. 1567
• Main Authors: Barroso, Tiago, Costa, Leila, Gonçalves, Lisa, Patel, Vanessa, Araújo, João, Pinho, Inês, Monteiro, Carolina, Esperança-Martins, Miguel, Abreu, Catarina, de Sousa, Rita Teixeira, Pais, Helena, Nogueira-Costa, Gonçalo, Torres, Sofia, Ribeiro, Leonor Abreu, da Costa, Luís Marques
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 05.05.2025; MDPI
• Subjects: Anemia; Antimitotic agents; Antineoplastic agents; Bayesian analysis; Blood; Breast cancer; Cancer; Cancer therapies; Care and treatment; Cell size; Clinical medicine; Cyclin-dependent kinase 4; Cyclin-dependent kinases; Data collection; Diagnosis; Dosage and administration; Drug dosages; Endocrine therapy; Erythrocytes; Estrogens; Evolution; Genetic aspects; Health aspects; Hematology; Hemoglobin; Homeostasis; Human subjects; Kinases; Laboratories; Life span; Mathematical models; Medical examination; Metastases; Metastasis; Neutropenia; Patients; Population dynamics; Thrombocytopenia; Toxicity; Portugal; breast cancer; hematological toxicity; CDK4/6 inhibitor; endocrine therapy; red blood cell

Background: CDK 4/6 inhibitors (CDK4/6is) are the first-line treatment for metastatic luminal-like breast cancer (BC). These drugs induce macrocytosis without anemia in most patients. The mechanism for the red blood cell (RBC) changes is unknown. In vitro and animal studies show that RBCs from CDK6-...